Influenza is associated with substantial morbidity and mortality each year in the United States. From 1976 to 2007, annual deaths from influenza ranged from approximately 3,300 to 49,000 (1). Vaccination against influenza has been recommended to prevent illness and related complications, and since 2010, the Advisory Committee on Immunization Practices has recommended that all persons aged ≥6 months be vaccinated against influenza each year (2). In 2013, CDC published a model to quantify the annual number of influenza-associated illnesses and hospitalizations averted by influenza vaccination during the 2006–11 influenza seasons (3). Using that model with 2012–13 influenza season vaccination coverage rates, influenza vaccine effectiveness, and influenza hospitalization rates, CDC estimated that vaccination resulted in 79,000 (17%) fewer hospitalizations during the 2012–13 influenza season than otherwise might have occurred. Based on estimates of the percentage of influenza illnesses that involve hospitalization or medical attention, vaccination also prevented approximately 6.6 million influenza illnesses and 3.2 million medically attended illnesses. Influenza vaccination during the 2012–13 season produced a substantial reduction in influenza-associated illness. However, fewer than half of persons aged ≥6 months were vaccinated. Higher vaccination rates would have resulted in prevention of a substantial number of additional cases and hospitalizations.

CDC used a model published in 2013 (3) to estimate an annual burden of influenza-associated outcomes prevented by influenza vaccination. All data inputs and estimates were stratified by age group: 6 months–4 years, 5–19 years, 20–64 years, and ≥65 years (Table 1). The disease burden during the 2012–13 influenza season was estimated in the following steps. First, laboratory-confirmed influenza-associated hospitalization rates were obtained from FluSurv-NET, a collaboration between CDC, the Emerging Infections Program Network, and selected health departments in 14 geographically distributed areas in the United States that conduct population-based surveillance. Hospitalization rates were adjusted for underreporting based on surveys conducted during the 2009 influenza pandemic; rates were increased by a factor of 2.74 for all age categories (3). Influenza illnesses were extrapolated from hospitalization data based on multipliers to reflect the percentage of ill persons who are hospitalized. Multipliers were age group–specific: 143.4 for 0–4 years; 364.7 for 5–19 years; 148.2 for 20–64 years, and 11.0 for ≥65 years. The percentage of ill persons who sought medical attention was estimated from the Behavioral Risk Factor Surveillance Survey (BRFSS) (3): 67% for persons aged 0–4 years; 51% for ages 5–19 years; 37% for ages 20–64 years, and 56% for ages ≥65 years. Second, 2012–13 vaccination coverage and vaccine effectiveness data were used to estimate the size of the susceptible population that was unprotected by vaccination and at risk of these outcomes. The rate of each outcome among susceptible persons was calculated as the number of estimated outcomes divided by the number of susceptible persons. This rate was then used to estimate the number of influenza-associated outcomes that would have occurred in a hypothetical, unvaccinated, susceptible population. Estimates of 2012–13 seasonal influenza vaccination coverage were based on self-report or parental report of vaccination status using data from the National Immunization Survey for children aged ≥6 months–17 years and BRFSS for adults aged ≥18 years,* and varied from 35.8 to 69.3, depending on the age group (Table 1). Vaccine effectiveness estimates were derived from the U.S. Influenza Vaccine Effectiveness (Flu VE) Network, a group of five academic institutions that conduct annual vaccine effectiveness studies, and varied from 32% among persons aged ≥65 years to 58% among children aged 6 months–4 years (4). Finally, the averted outcomes attributable to vaccination were estimated as the difference between outcomes in the hypothetical unvaccinated population and the observed population (3). The prevented fraction was calculated as the number of averted illnesses divided by the total illnesses that would have been expected in an unvaccinated population.

From October 2012 to May 2013, influenza vaccination resulted in an estimated 6.6 million (95% confidence interval [CI] = 4,011,725–10,551,756) fewer illnesses, 3.2 million (CI = 1,911,592–5,206,874) fewer medically attended illnesses, and 79,260 (CI = 39,530–136,744) fewer hospitalizations (Table 2). Overall, 17.3% (CI = 16.2%–18.0%) of adverse health outcomes associated with influenza were prevented. Although 29% of the averted illnesses and 39% of averted medically attended illnesses were among children aged 6 months–4 years and persons aged ≥65 years (two groups known to be at higher risk for complications), these two age groups accounted for 69% of averted hospitalizations. Vaccination had a substantial impact on averted hospitalizations in persons aged ≥65 years. Although persons aged ≥65 years accounted for 7% of the prevented illnesses and 8% of medically attended illnesses, 56% of all hospitalizations prevented were in those aged ≥65 years. If vaccination levels had reached the Healthy People 2020

* Methods for estimating season-specific influenza vaccination coverage and descriptions of National Immunization Survey and BRFSS data are available at http://www.cdc.gov/mmwr/pdf/ss/ss6204.pdf.
TABLE 1. Variables affecting impact of influenza vaccination, by age group — United States, 2012–13 influenza season

| Age group (yrs) | Cumulative vaccine coverage (%)* | Vaccine effectiveness (%)† | Total population§ | Cumulative hospitalization rate (per 100,000)§ | Estimated hospitalizations** | Estimated medically attended cases†† | Estimated cases‡‡ |
|----------------|----------------------------------|---------------------------|------------------|---------------------------------------------|-------------------------------|--------------------------------------|------------------|
| 6 mos–4        | 69.3 (67.8–70.8)                 | 58.0 (40–71)              | 17,879,414       | 49.7                                         | 24,354 (15,224–38,206)       | 3,493,384 (2,183,709–5,480,282) |
| 5–19           | 48.5 (47.6–49.4)                 | 64.0 (32–57)              | 62,505,456       | 13.3                                         | 22,746 (14,172–35,852)       | 1,325,672 (871,647–1,968,414)     |
| 20–64          | 35.8 (35.2–36.4)                 | 52.0 (43–60)              | 188,263,884      | 23.1                                         | 119,167 (78,995–177,656)     | 17,660,591 (11,707,096–26,328,640)|
| ≥65            | 66.0 (65.2–66.8)                 | 32.0 (0–56)               | 43,145,356       | 182.0                                        | 215,206 (142,909–316,950)     | 3,811,793 (2,531,272–5,645,849)   |
| All ages       | 44.7 (44.3–45.1)                 | 51.0 (45–57)              | 311,794,110      | 42.0                                         | 381,474 (251,300–568,665)     | 33,816,763 (20,631,339–48,370,938)|

Abbreviation: CI = confidence interval.

* Season-cumulative vaccine coverage rates calculated using data from the National Immunization Survey for children aged 6 months–17 years and from the Behavioral Risk Factor Surveillance System for adults aged ≥18 years. Model uses incremental monthly age-specific values. Estimates of the cumulative monthly proportion vaccinated through end of April of each season were developed using the Kaplan-Meier product limit method for receipt of most recent reported influenza vaccination. Negative lower 95% confidence intervals (CI) were revised to 0.
† Negative lower 95% CI intervals were revised to 0.
§ Calculated from U.S. Census Bureau annual estimates of the resident population by single year of age and sex for April 1, 2010 to July 1, 2012, available at [http://factfinder2.census.gov](http://factfinder2.census.gov)/faces/tableservices/jsf/pages/productview.xhtml?pid=PEP_2012_PEPSYASEX&prodType=table.
‡ Calculated using FluSurv-NET hospitalization rates adjusted for underreporting. The underreporting adjustment multiplier was calculated during the 2009–10 pandemic season and was 2.74 across age categories (3).
** Estimated using FluSurv-NET hospitalization rates adjusted for underreporting. The underreporting adjustment multiplier was calculated during the 2009–10 pandemic season and was 2.74 across age categories (3).
†† Based on the estimated number of cases and outpatient medically attended ratios by age group (3).
‡‡ Based on the estimated number of hospitalizations and age-specific case-hospitalization ratios for persons aged <65 years, and using a case-hospitalization ratio of 11:1 for persons aged ≥65 years (3).

TABLE 2. Estimated number of influenza cases averted by vaccination and the associated fraction prevented, by age group — United States, 2012–13 influenza season

| Age group (yrs) | Averted hospitalizations | Averted, medically attended cases | Averted cases | Fraction prevented |
|----------------|--------------------------|----------------------------------|---------------|--------------------|
| 0–4            | 10,216 (5,994–16,502)    | 981,851 (575,222–1,591,166)     | 1,465,450 (859,735–2,367,044) | 29.6 (28.0–30.2) |
| 5–19           | 4,770 (2,869–7,722)      | 887,256 (529,333–1,437,481)     | 1,739,713 (1,046,532–2,816,363) | 17.3 (16.8–17.8) |
| 20–64          | 19,813 (12,887–30,107)   | 1,086,409 (698,241–1,666,804)   | 2,340,565 (1,466,829–3,701,433) | 17.1 (10.5–21.3) |
| ≥65            | 36,460 (22,401–59,413)   | 3,325,536 (1,939,704–5,527,209) | 5,634,520 (3,160,787–9,598,644) | 29.6 (28.0–30.2) |
| All ages       | 79,260 (39,530–136,744)  | 3,229,393 (1,911,592–5,206,874) | 6,630,473 (4,011,725–10,551,756) | 17.3 (16.2–18.0) |

Abbreviation: CI = confidence interval.

National, regional, and state influenza surveillance data can be viewed at [http://www.cdc.gov/flu/fluactivitysurv.htm](http://www.cdc.gov/flu/fluactivitysurv.htm).

998

MMWR / December 13, 2013 / Vol. 62 / No. 49
effectiveness was lowest among persons aged ≥65 years, the relatively high vaccination coverage and high risk for severe outcomes resulted in substantial reductions in hospitalizations in this vulnerable group.

Fewer than half of persons in the United States are vaccinated each year (5), despite a recommendation for universal influenza vaccination for persons aged ≥6 months (3). Successful efforts to increase vaccination rates among all persons would increase the benefits of immunization programs on reducing illnesses. Strategies known to improve coverage should be encouraged. Those include ensuring that all those who visit a provider during the influenza season receive a vaccination recommendation and offer from their provider and using immunization information systems.§

Influenza vaccine effectiveness for the 2012–13 season was estimated to be 51% (CI = 45%–57%) (6), which is similar to estimates from recent seasons in the United States (2,4,6,7). Use of vaccines that are more effective would increase the number of averted ill and hospitalizations. However, despite a low measured vaccine effectiveness estimated to be 32% (CI = -5%–56%) among persons aged ≥65 years, vaccination likely produced substantial reductions in illness and hospitalizations because of the intensity of the 2012–13 epidemic and the relatively high vaccination coverage in this group compared with younger adults. Because most hospitalizations (8) and >90% of influenza deaths (1) occur in elderly persons, improving the ability of immunization programs to protect this vulnerable population will require vaccines with improved efficacy in elderly persons, along with continued efforts to increase vaccination rates. In 2010, a high-dose influenza vaccine (Fluzone HD, Sanofi Pasteur) was licensed for use in persons aged ≥65 years after prelicensure studies demonstrated superior immunogenicity compared with standard-dose vaccines (9). Final data from a recent efficacy trial are being analyzed.

The findings in this report are subject to at least six limitations. First, influenza vaccination coverage rates were derived from vaccination status reported by survey respondents, not vaccination records, and are subject to recall bias. Second, these rates are based on telephone surveys with relatively low response rates; therefore, selection bias might remain after weighting adjustments. Third, these surveys only cover the noninstitutionalized population. Fourth, estimates of the number of persons vaccinated based on these survey data exceeded the actual number of doses distributed, indicating coverage estimates used in this report overestimate averted illness resulting from vaccination (5). Fifth, the model only calculates outcomes directly averted by vaccination. If there is indirect protection from decreased exposure among unvaccinated persons in a partially vaccinated population (i.e., herd immunity), the model would underestimate the number of prevented illnesses. Also, although the impact of vaccination in preventing severe outcomes is most pronounced among persons aged ≥65 years, if vaccine effectiveness were lower among frail elderly persons, the model might have overestimated the effect in this group. Finally, adjustments for underreporting of influenza hospitalizations were based on studies conducted in 2009–10, as were the extrapolation of hospitalization rates to estimate rates of illness and medically attended illness. Because multipliers were calculated during a pandemic, if the ratio of hospitalizations to other outcomes or the underreporting of hospitalization rates were different in 2012–13 (e.g., through changes in health-seeking behaviors or testing practices), the model might have underestimated or overestimated the effect of vaccination.

Influenza vaccination prevents a substantial number of influenza-associated illnesses and hospitalizations. Although vaccines with increased effectiveness are needed, much can be done to maximize influenza prevention in the 2013–14 season.¶ In particular, efforts to increase vaccination rates will further reduce the burden of influenza. Although the timing and intensity of influenza circulation for the 2013–14 season cannot be predicted, peak weeks of influenza have occurred in January through March in >90% of seasons during the past 20 years, and significant circulation can occur as late as May.

§Evidence-based strategies for improving vaccination coverage are described in the Community Guide for Preventive Services, available at http://www.thecommunityguide.org/index.html.

¶Full influenza immunization recommendations and a list of available vaccines are available at http://www.cdc.gov/flu/protect/vaccine/index.htm.
Therefore, vaccination should be offered now and as long as influenza continues to circulate.

References
1. CDC. Estimates of deaths associated with seasonal influenza—United States, 1976–2007. MMWR 2010;59:1057–62.
2. CDC. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices—United States, 2013–2014. MMWR 2013;62(No. RR-7).
3. Kostova D, Reed C, Finelli L, et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005–2011. PloS One 2013;8:e66312.
4. Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012;55:951–9.
5. CDC. Flu vaccination coverage, United States, 2012–13 influenza season. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc.gov/flu/fluuvaxview/coverage-1213estimates.htm.
6. CDC. Advisory Committee on Immunization Practices (ACIP): summary report. June 19–20, 2013. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun13.pdf.
7. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013;56:1363–9.
8. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin Infect Dis 2012;54:1427–36.
9. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172–80.